COVID-19 vaccine implementation at a syringe services program: experiences of frontline staff.
COVID-19
People who inject drugs
Syringe services programs
Vaccines
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
19 Oct 2024
19 Oct 2024
Historique:
received:
25
06
2024
accepted:
01
10
2024
medline:
20
10
2024
pubmed:
20
10
2024
entrez:
19
10
2024
Statut:
epublish
Résumé
While people with substance use disorders, including people who inject drugs (PWID), experience increased risk for COVID-19 infection and adverse outcomes, COVID-19 vaccination rates among PWID are consistently lower than those observed in the general population. Offering COVID-19 vaccines at syringe services programs (SSPs) has been proposed as a critical strategy to increase vaccine uptake among this population. We explored the experiences of frontline staff at an SSP in Miami, Florida implementing onsite COVID-19 vaccines. Between June and July 2022, we conducted in-depth semi-structured interviews with 17 staff members of an SSP in Miami, Florida. Data collection and codebook thematic analysis of transcribed interviews were guided by the Consolidated Framework for Implementation Research (CFIR). Facilitators and barriers of COVID-19 vaccine implementation at the SSP aligned with all major CFIR domains. Key facilitators included the SSP's established partnership with the local health department for vaccine distribution, its existing funding sources which could be leveraged for vaccine-related expenses, consensus among staff about the need for new strategies to increase vaccine uptake among PWID, and PWID's trust in the SSP. Major-but largely modifiable-barriers included lack of participant compensation, limited internal collaboration and communication regarding the vaccine initiative beyond implementation leads and innovation deliverers due to competing priorities and segmented roles and responsibilities, and insufficient involvement of the most participant-facing staff (i.e., the SSP's peer navigators and outreach workers). Implementing onsite COVID-19 vaccines was perceived as feasible and acceptable by frontline staff at the SSP, however contextual factors impeded optimal implementation. Multilevel strategies, such as participant compensation for vaccine completion and internal educational meetings with staff to improve vaccine implementation and reach, are required. As a trusted source of preventative services for PWID, SSPs are an underutilized venue for increasing vaccine uptake among this population, and findings from this study could inform the expansion of low-barrier vaccine services at SSPs nationwide.
Sections du résumé
BACKGROUND
BACKGROUND
While people with substance use disorders, including people who inject drugs (PWID), experience increased risk for COVID-19 infection and adverse outcomes, COVID-19 vaccination rates among PWID are consistently lower than those observed in the general population. Offering COVID-19 vaccines at syringe services programs (SSPs) has been proposed as a critical strategy to increase vaccine uptake among this population. We explored the experiences of frontline staff at an SSP in Miami, Florida implementing onsite COVID-19 vaccines.
METHODS
METHODS
Between June and July 2022, we conducted in-depth semi-structured interviews with 17 staff members of an SSP in Miami, Florida. Data collection and codebook thematic analysis of transcribed interviews were guided by the Consolidated Framework for Implementation Research (CFIR).
RESULTS
RESULTS
Facilitators and barriers of COVID-19 vaccine implementation at the SSP aligned with all major CFIR domains. Key facilitators included the SSP's established partnership with the local health department for vaccine distribution, its existing funding sources which could be leveraged for vaccine-related expenses, consensus among staff about the need for new strategies to increase vaccine uptake among PWID, and PWID's trust in the SSP. Major-but largely modifiable-barriers included lack of participant compensation, limited internal collaboration and communication regarding the vaccine initiative beyond implementation leads and innovation deliverers due to competing priorities and segmented roles and responsibilities, and insufficient involvement of the most participant-facing staff (i.e., the SSP's peer navigators and outreach workers).
CONCLUSIONS
CONCLUSIONS
Implementing onsite COVID-19 vaccines was perceived as feasible and acceptable by frontline staff at the SSP, however contextual factors impeded optimal implementation. Multilevel strategies, such as participant compensation for vaccine completion and internal educational meetings with staff to improve vaccine implementation and reach, are required. As a trusted source of preventative services for PWID, SSPs are an underutilized venue for increasing vaccine uptake among this population, and findings from this study could inform the expansion of low-barrier vaccine services at SSPs nationwide.
Identifiants
pubmed: 39427164
doi: 10.1186/s12913-024-11691-9
pii: 10.1186/s12913-024-11691-9
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1260Subventions
Organisme : Department of Health & Human Services / NASTAD
ID : NU38OT000285
Organisme : Department of Health & Human Services / NASTAD
ID : NU38OT000285
Informations de copyright
© 2024. The Author(s).
Références
WHO. WHO Coronavirus (COVID-19) Dashboard Geneva. World Health Organization; Available from: https://covid19.who.int/
Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2021;26(1):30–9.
doi: 10.1038/s41380-020-00880-7
pubmed: 32929211
Strathdee SA, Abramovitz D, Harvey-Vera A, Vera CF, Rangel G, Artamonova I, et al. Prevalence and correlates of SARS-CoV-2 seropositivity among people who inject drugs in the San Diego-Tijuana border region. PLoS ONE. 2021;16(11):e0260286.
doi: 10.1371/journal.pone.0260286
pubmed: 34807963
pmcid: 8608290
Lim J, Pavalagantharajah S, Verschoor CP, Lentz E, Loeb M, Levine M, et al. Infectious diseases, comorbidities and outcomes in hospitalized people who inject drugs (PWID) infections in persons who inject drugs. PLoS ONE. 2022;17(4):e0266663.
doi: 10.1371/journal.pone.0266663
pubmed: 35443003
pmcid: 9020696
Cioffi CC, Kosty D, Nachbar S, Capron CG, Mauricio AM, Tavalire HF. COVID-19 vaccine deliberation among people who inject drugs. Drug Alcohol Depend Rep. 2022;3:100046.
doi: 10.1016/j.dadr.2022.100046
pubmed: 35345466
pmcid: 8942572
Iversen J, Wand H, Kemp R, Bevan J, Briggs M, Patten K, et al. Uptake of COVID-19 vaccination among people who inject drugs. Harm Reduct J. 2022;19(1):59.
doi: 10.1186/s12954-022-00643-3
pubmed: 35655217
pmcid: 9162792
Cepeda JA, Feder KA, Astemborski J, Schluth C, Kirk GD, Mehta SH, et al. COVID-19 vaccine hesitancy and vaccination status in a community-based cohort of people who inject drugs in Baltimore, Maryland, March-June 2021. Public Health Rep. 2022;137(5):1031–40.
doi: 10.1177/00333549221110299
pubmed: 35848111
pmcid: 9357826
Aronson ID, Bennett AS, Ardouin-Guerrier MA, Rivera-Castellar G, Gibson B, Santoscoy S, et al. How Vaccine Ambivalence can lead people who inject drugs to decline COVID-19 vaccination and Ways this can be addressed: qualitative study. JMIR Form Res. 2022;6(3):e35066.
doi: 10.2196/35066
pubmed: 35191841
pmcid: 8945077
Dietze PM, Hall C, Price O, Stewart AC, Crawford S, Peacock A, et al. COVID-19 vaccine acceptability among people in Australia who inject drugs: implications for vaccine rollout. Drug Alcohol Rev. 2022;41(2):484–7.
doi: 10.1111/dar.13399
pubmed: 34752659
Price O, Dietze PM, Maher L, Crawford S, Peacock A. COVID-19 vaccine acceptability among people in Australia who inject drugs: update from the 2021 Illicit Drug Reporting System interviews. Drug Alcohol Rev. 2022;41(5):1025–8.
doi: 10.1111/dar.13448
pubmed: 35184346
pmcid: 9111623
Arcadepani FB, De Macedo M, Tardelli VS, Martins SS, Fidalgo TM. COVID-19 vaccination among socially vulnerable people who use drugs. Addiction. 2021;116(9):2590–1.
doi: 10.1111/add.15500
pubmed: 33788354
pmcid: 8250779
Valasek CJ, Streuli SA, Pines HA, Mittal ML, Strathdee SA, Vera CF, et al. COVID-19 vaccination acceptability and experiences among people who inject drugs in San Diego County. Prev Med Rep. 2022;30:101989.
doi: 10.1016/j.pmedr.2022.101989
pubmed: 36148319
pmcid: 9484100
Strathdee SA, Abramovitz D, Vera CF, Artamonova I, Patterson TL, Smith DM, et al. Predictors of COVID-19 vaccine uptake among people who inject drugs. Vaccine. 2023;41(12):1916–24.
doi: 10.1016/j.vaccine.2023.01.042
pubmed: 36697311
pmcid: 9868393
Strathdee SA, Abramovitz D, Harvey-Vera A, Vera CF, Rangel G, Artamonova I et al. Correlates of Coronavirus Disease 2019 (COVID-19) vaccine hesitancy among people who inject drugs in the San Diego-Tijuana Border Region. Clin Infect Dis. 2021;5(1):e726-33.
Stack E, Shin S, LaForge K, Pope J, Leichtling G, Larsen JE, et al. COVID-19 vaccination status and concerns among people who use drugs in Oregon. J Addict Med. 2022;16(6):695-701.
Iversen J, Peacock A, Price O, Byrne J, Dunlop A, Maher L. COVID-19 vaccination among people who inject drugs: leaving no one behind. Drug Alcohol Rev. 2021;40(4):517–20.
doi: 10.1111/dar.13273
pubmed: 33650174
pmcid: 8013693
Montgomery MP, Zhong Y, Roberts E, Asher A, Bixler D, Doshani M, et al. Vaccination barriers and opportunities at syringe services programs in the United States, June-August 2021-A cross-sectional survey. Drug Alcohol Depend. 2022;237:109540.
doi: 10.1016/j.drugalcdep.2022.109540
pubmed: 35753280
pmcid: 11287426
Heidari O, Meyer D, O’Conor KJ, Cargill V, Patch M, Farley JE. COVID-19 vaccination and Communicable Disease Testing Services’ Integration within a Syringe services Program: a program brief. J Assoc Nurses AIDS Care. 2022;33(3):348–52.
doi: 10.1097/JNC.0000000000000322
pubmed: 35025822
Des Jarlais DC, Behrends CN, Corcorran MA, Glick SN, Perlman DC, Kapadia SN, et al. Availability of and obstacles to providing COVID-19 vaccinations at Syringe Services Programs in the United States, 2021. Public Health Rep. 2022;137(6):1066–9.
doi: 10.1177/00333549221120241
pubmed: 36113105
pmcid: 9574299
Carry M, Bixler D, Weng MK, Doshani M, Roberts E, Montgomery MP. Supporting syringe services programs in the initiation and scale-up of vaccine administration: findings from in-depth interviews. Harm Reduct J. 2022;19(1):100.
doi: 10.1186/s12954-022-00681-x
pubmed: 36050735
pmcid: 9435406
Heidari O, Meyer D, Lowensen K, Patil A, O’Conor KJ, LaRicci J, et al. Colocating Syringe Services, COVID-19 vaccination, and Infectious Disease Testing: Baltimore’s experience. Health Aff (Millwood). 2024;43(6):883–91.
doi: 10.1377/hlthaff.2024.00032
pubmed: 38830163
Corcorran MA, Austin EJ, Behrends CN, Briggs ES, Frost MC, Juarez AM, et al. Syringe Service Program perspectives on barriers, readiness, and programmatic needs to support rollout of the COVID-19 vaccine. J Addict Med. 2023;17(1):e36–41.
pubmed: 35916422
Stancliff S, Salomon N, Perlman DC, Russell PC. Provision of influenza and pneumococcal vaccines to injection drug users at a syringe exchange. J Subst Abuse Treat. 2000;18(3):263–5.
doi: 10.1016/S0740-5472(99)00064-1
pubmed: 10742640
Weiss D, Stern EJ, Zimmerman C, Bregman B, Yeung A, Das D, et al. Epidemiologic investigation and targeted vaccination initiative in response to an outbreak of meningococcal disease among illicit drug users in Brooklyn, New York. Clin Infect Dis. 2009;48(7):894–901.
doi: 10.1086/597257
pubmed: 19231975
Update: syringe exchange programs–United States. 1998. MMWR Morb Mortal Wkly Rep. 2001;50(19):384-7.
Des Jarlais DC, Fisher DG, Newman JC, Trubatch BN, Yancovitz M, Paone D, et al. Providing hepatitis B vaccination to injection drug users: referral to health clinics vs on-site vaccination at a syringe exchange program. Am J Public Health. 2001;91(11):1791–2.
doi: 10.2105/AJPH.91.11.1791
pubmed: 11684603
pmcid: 1446878
Altice FL, Bruce RD, Walton MR, Buitrago MI. Adherence to hepatitis B virus vaccination at syringe exchange sites. J Urban Health. 2005;82(1):151–61.
doi: 10.1093/jurban/jti016
pubmed: 15746385
pmcid: 3456633
Topp L, Day CA, Wand H, Deacon RM, van Beek I, Haber PS, et al. A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia. Prev Med. 2013;57(4):297–303.
doi: 10.1016/j.ypmed.2013.04.013
pubmed: 23639625
Bowman S, Grau LE, Singer M, Scott G, Heimer R. Factors associated with hepatitis B vaccine series completion in a randomized trial for injection drug users reached through syringe exchange programs in three US cities. BMC Public Health. 2014;14:820.
doi: 10.1186/1471-2458-14-820
pubmed: 25107530
pmcid: 4138371
Tressler S, Bhandari R. Interventions to increase completion of Hepatitis B vaccination in people who inject drugs: a systematic review and Meta-analysis. Open Forum Infect Dis. 2019;6(12):ofz521.
doi: 10.1093/ofid/ofz521
pubmed: 31890724
pmcid: 6929254
Alanko Blomé M, Björkman P, Flamholc L, Jacobsson H, Widell A. Vaccination against hepatitis B virus among people who inject drugs - a 20 year experience from a Swedish needle exchange program. Vaccine. 2017;35(1):84–90.
doi: 10.1016/j.vaccine.2016.11.041
pubmed: 27894721
Hu Y, Grau LE, Scott G, Seal KH, Marshall PA, Singer M, et al. Economic evaluation of delivering hepatitis B vaccine to injection drug users. Am J Prev Med. 2008;35(1):25–32.
doi: 10.1016/j.amepre.2008.03.028
pubmed: 18541174
pmcid: 2483306
Campbell JV, Garfein RS, Thiede H, Hagan H, Ouellet LJ, Golub ET, et al. Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users. Drug Alcohol Depend. 2007;91(Suppl 1):S64–72.
doi: 10.1016/j.drugalcdep.2006.09.022
pubmed: 17276018
Des Jarlais DC, Friedman SR. HIV epidemiology and interventions among injecting drug users. Int J STD AIDS. 1996;7(Suppl 2):57–61.
doi: 10.1258/0956462961917654
pubmed: 8799797
Centers for Disease Control and Prevention, Surveillance Report HIV. 2015. Atlanta: Centers for Disease Control and Prevention; 2016.
Centers for Disease Control and Prevention. NCHHSTP AtlasPlus Atlanta: Centers for Disease Control and Prevention. 2023 [ https://www.cdc.gov/nchhstp/atlas/index.htm
Bartholomew TS, Nakamura N, Metsch LR, Tookes HE. Syringe services program (SSP) operational changes during the COVID-19 global outbreak. Int J Drug Policy. 2020;83:102821.
doi: 10.1016/j.drugpo.2020.102821
pubmed: 32591222
pmcid: 7290194
Escudero DJ, Bennett B, Suarez S, Darrow WW, Mayer KH, Seage GR 3. Progress and challenges in getting to Zero New HIV infections in Miami, Florida. J Int Assoc Provid AIDS Care. 2019;18:2325958219852122.
doi: 10.1177/2325958219852122
pubmed: 31131664
pmcid: 6573019
Iyengar S, Kravietz A, Bartholomew TS, Forrest D, Tookes HE. Baseline differences in characteristics and risk behaviors among people who inject drugs by syringe exchange program modality: an analysis of the Miami IDEA syringe exchange. Harm Reduct J. 2019;16(1):7.
doi: 10.1186/s12954-019-0280-z
pubmed: 30674334
pmcid: 6343273
Bartholomew TS, Andraka-Cristou B, Totaram RK, Harris S, Doblecki-Lewis S, Ostrer L, et al. We want everything in a one-stop shop: acceptability and feasibility of PrEP and buprenorphine implementation with mobile syringe services for black people who inject drugs. Harm Reduct J. 2022;19(1):133.
doi: 10.1186/s12954-022-00721-6
pubmed: 36463183
pmcid: 9719627
University of Miami Miller School of Medicine. Miami-Dade County Sterile Needle and Syringe Exchange Program Annual Report. Miami: University of Miami Miller School of Medicine; 2023.
Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated Consolidated Framework for Implementation Research based on user feedback. Implement Sci. 2022;17(1):75.
doi: 10.1186/s13012-022-01245-0
pubmed: 36309746
pmcid: 9617234
APA handbook of research methods in psychology, Vol 2: Research designs: Quantitative, qualitative, neuropsychological, and biological. Cooper H, Camic PM, Long DL, Panter AT, Rindskopf D, Sher KJ, editors. Washington, DC, US: American Psychological Association. 2012. x, 701-x, p.
Creswell JW, Báez JC. 30 Essential Skills for the Qualitative Researcher. 2nd Edition ed. London: SAGE Publications, Inc.; 2021.
Storer D, Lafferty L, Graham S, Murphy D, Rance J, Brener L et al. Perceptions of COVID-19 Vaccines: Lessons from Selected Populations Who Experience Discrimination in the Australian Healthcare System. Health & Social Care in the Community. 2023;2023:5901128.
Hardin B, Graboyes M, Kosty D, Cioffi C. Vaccine decision making among people who inject drugs: improving on the WHO’s 3 C model of vaccine hesitancy. Prev Med Rep. 2023;35:102341.
doi: 10.1016/j.pmedr.2023.102341
pubmed: 37593355
pmcid: 10428103
Harvey-Vera A, Munoz S, Artamonova I, Abramovitz D, Mittal ML, Rosales C, et al. COVID-19 vaccine uptake among people who inject drugs in Tijuana Mexico. Front Public Health. 2022;10:931306.
doi: 10.3389/fpubh.2022.931306
pubmed: 36148330
pmcid: 9485825